Navigation Links
Immunodeficiency in Biological Technology

GeoVax Labs, Inc. Provides Clinical Studies Update

... will recall that trials conducted using a simian immunodeficiency virus (SIV) prototype of the GeoVax HIV vaccine ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois

... vaccines for diseases caused by the HIV-1 (Human immunodeficiency Virus), and other infectious agents, announced ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results

... on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Update Provided at the BIO CEO & Investor Conference 2009

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, today ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax to Present at the BIO CEO & Investor Conference 2009

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Labs, Inc. Information To Be Available Through Standard & Poor's Market Access Program

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update

... study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients

... patients with primary immunodeficiency. Primary immunodeficiency is a group of genetic disorders in which the ... improving the diagnosis and treatment of primary immunodeficiency diseases through research, education and ... the only abnormality of concern. About Primary immunodeficiency Disorders ...

GeoVax Labs, Inc. Announces Resignation of Director

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance

... an antiretroviral therapy. About HIV and AIDS HIV, or the human immunodeficiency virus, is a retrovirus that infects cells of the human immune system, ... West Africa. The most advanced stage of HIV infection is AIDS, or acquired immunodeficiency syndrome. HIV can take up to 15 years to develop into AIDS, a process that ...

GeoVax Labs, Inc. Announces First Quarter Financial Results

... focused on developing human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's HIV/AIDS vaccine technology ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

GeoVax Presents Data at AIDS Vaccine 2008 Conference

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

Researchers decode viral process that prepares cells for HIV infection

... the medical community is one step closer to understanding how the human immunodeficiency virus (HIV) attacks cells in the immune system. AIDS, which is caused by ... by the virus. HIV-1 infection causes CD4 T-cell depletion that leads to immunodeficiency and AIDS. During the six-year study, a team largely comprised of ...

Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program

... of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close ...

Mymetics Corporation Important Shareholders Information Conference Call

... of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close ...

Pharmasset Appoints Michael Rogers as Chief Development Officer

... responsible for antiviral discovery activities directed toward human immunodeficiency virus (HIV) and hepatitis C virus (HCV) indications. Dr. Rogers has over ... treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. ...

U.S. Government Awards $15 Million Grant to GeoVax Labs' HIV/AIDS Vaccine Program

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ... GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating ...

FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox

... to smallpox. ACAM2000 is contraindicated for individuals with severe immunodeficiency who are not expected to benefit from the vaccine. These individuals may ... undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation. - The most serious adverse events ...

GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update

... HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating ... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ...

Pharmasset to Present at Canaccord Adams Conference

... of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the ...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

... of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for ...

LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record

... its pDNA and rVSV platforms via a unique prime boost strategy to enhance immune response. Profectus' broad product pipeline will address Human immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV). The Profectus portfolio has received over ...

Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates

... particles from the human circulatory system. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier(R) also holds ...

Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results

... completed a phase I/II proof-of-concept study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus (HIV) in September 2008. In February 2009, the company announced that it had licensed its NNRTI program, including IDX899, to GlaxoSmithKline ...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling ...

Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS

... and destruction leaving them able fight opportunistic infections and HIV itself. About HIV/AIDS and CCR5 HIV stands for Human immunodeficiency Virus. HIV infection kills or impairs cells of the immune system progressively destroying the body's ability to fight infections and certain cancers ...

Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Forward-Looking Statements Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: ...

Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling ...

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

... KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze(TM) Technology) for the treatment of primary immunodeficiency (PID). The purpose of this clinical trial is to evaluate the safety and efficacy and gain regulatory approval for the treatment of PID using ...

Pharmasset to Present at Two Upcoming Investor Conferences

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic

... could be produced in quantities required for the translation of this program into the clinic. About HIV/AIDS and CCR5 HIV stands for Human immunodeficiency Virus. HIV infection kills or impairs cells of the immune system, progressively destroying the body's ability to fight infections and certain cancers ...

Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines

... in early 2005 to develop and commercialize technologies to reduce the morbidity and mortality caused by human viral diseases, including the human immunodeficiency virus (HIV), the causative agent of AIDS. Founded to fulfill the mission of its co-founders Drs. Gallo, Blattner, and Redfield (collectively, the ...

Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV

... (NASDQ: ROSG) announced today a collaboration with the National Institute of Health to identify microRNAs involved in the progression of the Human immunodeficiency Virus (HIV), that may be used as potential drug targets. Rosetta Genomics has access to the majority of known human and viral microRNAs. From this ...
Other Contents
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
(Date:12/24/2014)... 2014 The report “Stivarga (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... a drug which is used in the treatment of ... and is also prescribed to patients who suffer from ... approved is a multi-kinase inhibitor and it blocks many ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... one year will be allowed to donate blood in the United ... ban on donations from men who have sex with men. ... release a new draft guidance in early 2015 that would ultimately ... FDA is changing its policy based on data from other countries ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A new, ... Food and Drug Administration. The agency on Tuesday ... for those who are overweight and have at least ... type 2 diabetes or high cholesterol. Patients taking ... a low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... are more likely to start smoking or drinking with ... (ADHD) or conduct disorder, new research suggests. ... the risk of substance use as [these] children approach ... at Cincinnati Pediatric Research Group, which is part of ...
(Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
Breaking Medicine News(10 mins):Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
Other TagsOther Tags